Open Health acquires US-based Acsel Health

21 February 2023 2 min. read

Open Health, a London-based life sciences consulting firm, has acquired Acsel Health, a life sciences consultancy based in New York.

Founded in 2013, Acsel advises pharma and biotech companies on commercial strategy and excellence, market access, and business development. The firm’s offerings include go-to-market strategy, lifecycle management, pricing and reimbursement, portfolio optimization, and transaction support.

Acsel has 44 employees listed on LinkedIn.

Open Health’s acquisition of Acsel will complement its current services offerings in health economics and outcomes research (HEOR) and market access, medical communications, and omnichannel campaigns. The transaction – for which financial terms were not disclosed – will also expand Open Health’s physical presence into New York City.

“Acsel’s expert team and long-standing client relationships significantly strengthen our ability to support the commercialization of our clients’ assets and unlock access for patients.” said Rob Barker, CEO of Open Health. “We are excited to welcome Acsel Health into the OPEN Health Group and look forward to working with our new colleagues to offer our clients innovative, scientific solutions around the globe.”

Open Health acquires US-based Acsel Health

Open Health was founded in 2011 and has more than 1,100 employees in the UK, Germany, The Netherlands, India, China, and the US. The firm has two offices in New Jersey and an office in Boston (the traditional centers for the US pharmaceutical industry), as well as a location in Chicago.

The British firm’s offerings span market access strategy, health economic modeling, patient engagements, medical affairs consulting, scientific communications, and learning and development.

“We are thrilled to join OPEN Health and to work with a wider team to solve for today’s demands and meet tomorrow’s expectations for pharma and biotech customers,” Lujing Wang, managing partner of Acsel Health, said. “With new colleagues and capabilities to partner with, we are equipped to answer the most challenging cross-disciplinary questions in life science across all key therapeutic areas.”

Fairmount Partners, a Philadelphia-based investment bank, acted as exclusive financial advisor to Acsel on the transaction.